✦ LIBER ✦

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

✍ Scribed by Thomas M. Habermann; Izidore S. Lossos; Glen Justice; Julie M. Vose; Peter H. Wiernik; Kyle McBride; Kenton Wride; Annette Ervin-Haynes; Kenichi Takeshita; Dennis Pietronigro; Jerome B. Zeldis; Joseph M. Tuscano

Book ID: 108676232
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 154 KB
Volume: 145
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2009.07626.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 trial of rituximab and bortezomi

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma

✍ Robert A. Baiocchi; Lapo Alinari; Mark E. Lustberg; Thomas S. Lin; Pierluigi Por 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB 👁 1 views

High-dose chemotherapy and autologous st

High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma

✍ El Weshi, A; Rahal, M; Abdelsalam, M; Al Husseini, H; Maghfoor, I; Akhtar, S 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 200 KB

Relevance of monitoring metabolic reduct

Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study

✍ Ukihide Tateishi; Mitsuaki Tatsumi; Takashi Terauchi; Kenichi Ishizawa; Michinor 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

A multicentre phase II clinical experien

A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

✍ Owen A. O’Connor; Carol Portlock; Craig Moskowitz; David Straus; Paul Hamlin; Mi 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

Patients with chemotherapy-refractory ma

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial

✍ Owen A. O’Connor; Craig Moskowitz; Carol Portlock; Paul Hamlin; David Straus; Ot 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

High response rate to bortezomib with or

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

✍ Joseph R. Mikhael; Andrew R. Belch; H. Miles Prince; Maria Nambo Lucio; Angelo M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 272 KB